E sophageal adenocarcinoma (EAC) has sobering incidence and mortality statistics over the last several decades. The incidence of EAC has risen 7-fold from 1975 to 2016, according to data from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute. 1 Despite screening and surveillance programs and improved treatment paradigms for Barrett's esophagus (BE), as much as 40% of EACs present with advanced disease, with a dismal 5-year survival rate. 2 Several factors contribute to this. Curable EAC has no reliable presenting symptom, and population-based screening of at-risk individuals is not effective because of low EAC incidence. Targeted screening for BE within gastroesophageal reflux disease (GERD) populations also has limitations, as only 7%-10% of individuals with chronic GERD have BE, nearly 40% of EAC patients describe no history of GERD, and up to 50% of patients with short-segment BE lack GERD symptoms. 3 In addition, use of endoscopy as a screening tool is compromised by expense, facility/physician expertise needed, and limited effectiveness, because >90% of EACs do not have a prior BE diagnosis. 4 Broadening the at-risk population to include risk factors independent of GERD (age >50 years, male sex, white race, cigarette smoking, and central obesity) would incur increased resource utilization, costs, and potential harm from endoscopy. Similarly, BE surveillance endoscopy also has limitations. Compliance with guideline recommendations for appropriate endoscopic surveillance intervals with application of the Seattle protocol is suboptimal. 3,5 Data from the GI Quality Improvement Consortium registry demonstrated that 30% of patients with nondysplastic BE undergo endoscopy earlier than guideline recommendation without strict adherence to the Seattle protocol. 6,7 Current surveillance programs are time consuming, and there is potential for sampling errors with even the most thorough surveillance programs. Finally, significant inter-and intra-observer variability exists among both community and expert pathologists in dysplasia interpretation. 3 Even in the face of suboptimal impact of current strategies on population-based EAC mortality, medical societies consistently recommend BE screening and surveillance. 3,5,8 In this context, similar to post-colonoscopy colorectal cancer (PCCRC), the concept of missed EAC is gaining importance in endoscopic BE screening and surveillance. The aims of this review of literature pertaining to post-endoscopy esophageal adenocarcinoma (PEEC) are to lay the groundwork for standardizing terminology and definitions for Most current article